Corcept combines several strengths that are relatively uncommon in its peer group: it is profitable, generates solid free cash flow, and maintains a strong, cash-rich balance sheet with very little debt. Its scientific focus on cortisol modulation is deep and differentiated, supported by decades of research and a broad internal compound portfolio. The company already has commercial experience in a rare endocrine disease, established specialist relationships, and significant retained earnings to fund ambitious R&D. These factors give it both financial resilience and genuine optionality as it pursues larger markets.

The largest risk is the expected decline of Korlym revenue due to generic entry and competitive therapies, which could compress margins and reduce the cash available to fund the pipeline. High ongoing spending on selling, administrative functions, and R&D means profitability is sensitive to any revenue shortfall. Pipeline risk is also substantial: relacorilant’s delay in Cushing’s underscores regulatory uncertainty, and future success in oncology, ALS, and MASH is not guaranteed. Concentration around a single biological pathway and a handful of key late-stage assets further heightens the impact of any clinical or regulatory setback. Aggressive share repurchases add another dimension of risk if they were to materially weaken the balance sheet in a tougher operating environment.

Looking ahead, Corcept appears to be at an inflection point. The legacy Cushing’s business has funded a strong financial position and a wide-ranging pipeline, but that legacy franchise is heading into a more challenging, competitive phase. The medium- to long-term outlook will depend primarily on whether the company can successfully transition from a one-product endocrinology business to a multi-product platform company with meaningful exposure to oncology and other large diseases. Its cash generation and balance sheet give it time and resources to attempt this transition, but the outcome will hinge on clinical trial results, regulatory decisions, and the company’s ability to convert scientific advantage into clear, differentiated therapies in crowded markets.